Alzinova AB is engaged in drug discovery research for Alzheimer’s disease. The company’s proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer’s disease research.
More information about Alzinova can be found on the company’s home page (www.alzinova.com).
Contact: Any questions or requests for more information may be directed to Alzinova’s management team at email@example.com.